Discover our world-class diagnostic services

Expand your diagnostic capabilities and empower your doctors & patients to make better health decisions with our actionable health insights. Our best-in-class NGS-based diagnostic services will give you the information you need – when you need it.

DeltaGene services

Hereditary tumor diagnostics

Gain insights into patients’ genetic profiles to discover their genetic predispositions to various cancers. Our actionable insights & guidelines help doctors and patients craft more informed, personalized prevention strategies. Recommended in cases of suspected predisposition (such as a personal or family history of cancer), as well as just to gain a deeper understanding of one’s health.

DNA – Hematopoetic Cancer – Hereditary 29

Read more

DNA – Hematopoetic Cancer – Hereditary 15

Read more

DNA – Hematopoetic Cancer – Hereditary 14

Read more

DNA – Skin Cancer – Hereditary 26

Read more

DNA – Skin Cancer – Hereditary 19

Read more

DNA – Skin Cancer – Hereditary 7

Read more

DNA – PRU Cancer – Hereditary 36

Read more

DNA – PRU Cancer –Hereditary 20

Read more

DNA – PRU Cancer – Hereditary 16

Read more

DNA – Endocrine Cancer – Hereditary 37

Read more

DNA – Endocrine Cancer – Hereditary 18

Read more

DNA – Endocrine Cancer – Hereditary 19

Read more

DNA – Breast Ovary Cancer – Hereditary 25

Read more

DNA – Breast Ovary Cancer – Hereditary 3

Read more

DNA – Breast Ovary Cancer – Hereditary 22

Read more

DNA – Colorectal Cancer – Hereditary 24

Read more

DNA – Colorectal Cancer – Hereditary 10

Read more

DNA – Colorectal Cancer – Hereditary 14

Read more

DNA – Neural Cancer – Hereditary 34

Read more

DNA – Neural Cancer – Hereditary 22

Read more

DNA – Neural Cancer – Hereditary 12

Read more

DNA – Pan Cancer – Hereditary 100

Read more

DNA – Pan Cancer – Hereditary 69

Read more

DNA – Pan Cancer – Hereditary 31

Read more

DNA – BRCA1/BRCA2 – Hereditary Focus

Read more

DNA – BRCA1/BRCA2 – Hereditary

Read more

Solid tumor diagnostics

Identify the genetic mutations & alterations that drive tumor growth and resistance to certain therapies – and always make informed decisions about the best course of action. Our comprehensive NGS solid tumor reports help oncologists and patients confirm a diagnosis, select targeted therapies, monitor disease progressions, or assess eligibility to clinical trials.

RNA – Prostate Cancer – Solid 13

Read more

DNA – Melanoma Cancer – Solid 10

Read more

DNA – Lung Cancer – Solid 14

Read more

DNA – Breast Cancer – Solid 12

Read more

DNA – Melanoma Cancer – Solid 76

Read more

DNA – Melanoma Cancer – Solid 41

Read more

DNA – Colorectal Cancer – Solid 93

Read more

DNA – Colorectal Cancer – Solid 43

Read more

DNA – Lung Cancer – Solid 78

Read more

DNA – Lung Cancer – Solid 46

Read more

DNA – BRCA1/BRCA2 – Solid

Read more

DNA – Breast Cancer – Solid 47

Read more

DNA – Breast Cancer – Solid 28

Read more

DNA – Breast Cancer – Solid 28

Read more

DNA – Pan Cancer – Solid 109

Read more

Liquid biopsy diagnostics

Gain access to a fast, accurate, and convenient method to track cancer progression and therapy response. Our liquid biopsy services identify the genetic mutations & changes in circulating tumor DNA (ctDNA) from blood. Recommended for tailoring treatment plans, monitoring responses, or detecting signs of recurrence or therapy resistance. Also suitable to complement (or replace) tissue biopsy – which is often invasive, painful, and limited by tumor heterogeneity.

DNA – Melanoma Cancer – Plasma Focus

Read more

DNA – Melanoma Cancer – Plasma 10

Read more

DNA – Lung Cancer – Plasma 14

Read more

DNA – EGFR – Plasma Focus

Read more

Microbiome diagnostics

Identify & quantify microorganisms from stool samples to gain insights into gut health, diversity, and function. Our comprehensive microbiome report offers personalized recommendations on how to improve your gut microbiome and overall wellness. Recommended for optimizing digestion, immunity, mood, or bodyweight.

DNA – Gut Microbiome Bacterial – Shotgun

Read more

DNA – Hematopoetic Cancer – Hereditary 29

Available

Genes:

ATM, BRIP1, EPCAM, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, RAD50, TP53, BLM, SLX4, NF1, TERT*, GATA2, SBDS, RUNX1, HRAS*, PRF1, FANCD2, FANCE, FANCF, FANCG, MPL, FANCC, FANCA, FANCB

Useful for:

Our DNA – Hematopoetic Cancer – Hereditary 29 Panel is a targeted resequencing assay for the biomarker analysis of 29 genes with known relevance to hereditary hematopoetic tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 29 genes known to be associated with hereditary hematopoetic cancer syndromes.

DNA – Hematopoetic Cancer – Hereditary 15

Available

Genes:

NF1, TERT*, GATA2, SBDS, RUNX1, HRAS*, PRF1, FANCD2, FANCE, FANCF, FANCG, MPL, FANCC, FANCA, FANCB

Useful for:

Our DNA – Hematopoetic Cancer – Hereditary 15 Panel is a targeted resequencing assay for the biomarker analysis of 15 genes with known relevance to hereditary hematopoetic tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 15 genes known to be associated with hereditary hematopoetic cancer syndromes.

DNA – Hematopoetic Cancer – Hereditary 14

Available

Genes:

ATM, BRIP1, EPCAM, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, RAD50, TP53, BLM, SLX4

Useful for:

Our DNA – Hematopoetic Cancer – Hereditary 14 Panel is a targeted resequencing assay for the biomarker analysis of 14 genes with known relevance to hereditary hematopoetic tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 14 genes known to be associated with hereditary hematopoetic cancer syndromes.

DNA – Skin Cancer – Hereditary 26

Available

Genes:

BRCA2, CDK4, CDKN2A, MSH2, PTEN, TP53, BLM, BAP1, FH, FLCN, MITF, POT1, PTCH1, RB1, KIT*, TERT*, KDR, CYLD*, DDB2, ERCC2, ERCC3*, ERCC4, ERCC5, RECQL4, XPA, XPC

Useful for:

Our DNA – Skin Cancer – Hereditary 26 Panel is a targeted resequencing assay for the biomarker analysis of 26 genes with known relevance to hereditary melanomas and skin cancer formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 26 genes known to be associated with hereditary melanomas and skin cancer syndromes.

DNA – Skin Cancer – Hereditary 19

Available

Genes:

BAP1, FH, FLCN, MITF, POT1, PTCH1, RB1, KIT*, TERT*, KDR, CYLD*, DDB2, ERCC2, ERCC3*, ERCC4, ERCC5, RECQL4, XPA, XPC

Useful for:

Our DNA – Skin Cancer – Hereditary 19 Panel is a targeted resequencing assay for the biomarker analysis of 19 genes with known relevance to hereditary melanomas and skin cancer formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 19 genes known to be associated with hereditary melanomas and skin cancer syndromes.

DNA – Skin Cancer – Hereditary 7

Available

Genes:

BRCA2, CDK4, CDKN2A, MSH2, PTEN, TP53, BLM

Useful for:

Our DNA – Skin Cancer – Hereditary 7 Panel is a targeted resequencing assay for the biomarker analysis of 7 genes with known relevance to hereditary melanomas and skin cancer formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 7 genes known to be associated with hereditary melanomas and skin cancer syndromes.

DNA – PRU Cancer – Hereditary 36

Available

Genes:

ATM, BRCA1, BRCA2, CHEK2, NBN, RAD51D, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, TP53, STK11, VHL, BAP1, FH, FLCN, MET*, MITF, SDHA, SDHB, SDHC, SDHD*, SMARCA4, SMARCB1, TMEM127, TSC1, TSC2, CDC73, GPC3, WT1, CEP57, BUB1B, HOXB13

Useful for:

Our DNA – PRU Cancer – Hereditary 36 Panel is a targeted resequencing assay for the biomarker analysis of 36 genes with known relevance to hereditary Prostate, Renal and Urinary tract tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 36 genes known to be associated with hereditary prostate, renal, and urinary tract cancer syndromes.

DNA – PRU Cancer –Hereditary 20

Available

Genes:

BAP1, FH, FLCN, MET*, MITF, SDHA, SDHB, SDHC, SDHD*, SMARCA4, SMARCB1, TMEM127, TSC1, TSC2, CDC73, GPC3, WT1, CEP57, BUB1B, HOXB13

Useful for:

Our DNA – PRU Cancer – Hereditary 20 Panel is a targeted resequencing assay for the biomarker analysis of 20 genes with known relevance to hereditary Prostate, Renal, and Urinary tract tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 20 genes known to be associated with hereditary prostate, renal, and urinary tract cancer syndromes.

DNA – PRU Cancer – Hereditary 16

Available

Genes:

ATM, BRCA1, BRCA2, CHEK2, NBN, RAD51D, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, TP53, STK11, VHL

Useful for:

Our DNA – PRU Cancer – Hereditary 16 Panel is a targeted resequencing assay for the biomarker analysis of 16 genes with known relevance to hereditary Prostate, Renal, and Urinary tract tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 16 genes known to be associated with hereditary prostate, renal, and urinary tract cancer syndromes.

DNA – Endocrine Cancer – Hereditary 37

Available

Genes:

APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, TP53, VHL, PRSS1, CHEK2, PTEN, STK11, MEN1, NF1, TSC1, TSC2, CDKN1B, FH, MAX, PRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD*, TMEM127, CDC73, WRN, HNF1A

Useful for:

Our DNA – Endocrine Cancer – Hereditary 37 Panel is a targeted resequencing assay for the biomarker analysis of 37 genes with known relevance to hereditary pancreas and endocrine tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 37 genes known to be associated with hereditary pancreas and endocrine cancer syndromes.

DNA – Endocrine Cancer – Hereditary 18

Available

Genes:

MEN1, NF1, TSC1, TSC2, CDKN1B, FH, MAX, PRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD*, TMEM127, CDC73, WRN, HNF1A

Useful for:

Our DNA – Endocrine Cancer – Hereditary 18 Panel is a targeted resequencing assay for the biomarker analysis of 18 genes with known relevance to hereditary pancreas and endocrine tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 18 genes known to be associated with hereditary pancreas and endocrine cancer syndromes.

DNA – Endocrine Cancer – Hereditary 19

Available

Genes:

APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, TP53, STK11, VHL, CHEK2, PTEN, PRSS1

Useful for:

Our DNA – Endocrine Cancer – Hereditary 19 Panel is a targeted resequencing assay for the biomarker analysis of 19 genes with known relevance to hereditary endocrine tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 19 genes known to be associated with hereditary endocrine cancer syndromes.

DNA – Breast Ovary Cancer – Hereditary 25

Available

Genes:

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, TP53, STK11, NF1, RB1, SMARCA4

Useful for:

Our DNA – Breast Ovary Cancer – Hereditary 25 Panel is a targeted resequencing assay for the biomarker analysis of 25 genes with known relevance to hereditary breast and ovary tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 25 genes known to be associated with hereditary breast and ovary cancer syndromes.

DNA – Breast Ovary Cancer – Hereditary 3

Available

Genes:

NF1, RB1, SMARCA4

Useful for:

Our DNA – Breast Ovary Cancer – Hereditary 3 Panel is a targeted resequencing assay for the biomarker analysis of 3 genes with known relevance to hereditary breast and ovary tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 3 genes known to be associated with hereditary breast and ovary cancer syndromes.

DNA – Breast Ovary Cancer – Hereditary 22

Available

Genes:

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, TP53, STK11

Useful for:

Our DNA – Breast Ovary Cancer – Hereditary 22 Panel is a targeted resequencing assay for the biomarker analysis of 22 genes with known relevance to hereditary breast and ovary tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 22 genes known to be associated with hereditary breast and ovary cancer syndromes.

DNA – Colorectal Cancer – Hereditary 24

Available

Genes:

APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, TP53, STK11, GREM1, POLE, TGFBR2, NF1, SDHA, SDHB, SDHC, SDHD*, KIT*, PDGFRA

Useful for:

Our DNA – Colorectal Cancer – Hereditary 24 Panel is a targeted resequencing assay for the biomarker analysis of 24 genes with known relevance to hereditary colorectal tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 24 genes known to be associated with hereditary colorectal cancer syndromes.

DNA – Colorectal Cancer – Hereditary 10

Available

Genes:

GREM1, POLE, TGFBR2, NF1, SDHA, SDHB, SDHC, SDHD*, KIT*, PDGFRA

Useful for:

Our DNA – Colorectal Cancer – Hereditary 10 Panel is a targeted resequencing assay for the biomarker analysis of 10 genes with known relevance to hereditary colorectal tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 10 genes known to be associated with hereditary colorectal cancer syndromes.

DNA – Colorectal Cancer – Hereditary 14

Available

Genes:

APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, TP53, STK11

Useful for:

Our DNA – Colorectal Cancer – Hereditary 14 Panel is a targeted resequencing assay for the biomarker analysis of 14 genes with known relevance to hereditary colorectal tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 14 genes known to be associated with hereditary colorectal cancer syndromes.

DNA – Neural Cancer – Hereditary 34

Available

Genes:

APC, ATM, CDKN2A, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, TP53, VHL, ALK, CDKN1B, MEN1, NF1, NF2, PHOX2B, POT1, PRKAR1A, PTCH1, RB1, SDHA, SDHAF2, SDHB, SDHD*, SMARCA4, SMARCB1, SMARCE1, SUFU, TSC1, TSC2, GPC3, WRN

Useful for:

Our DNA – Neural Cancer – Hereditary 34 Panel is a targeted resequencing assay for the biomarker analysis of 34 genes with known relevance to hereditary neural tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 34 genes known to be associated with hereditary neural cancer syndromes.

DNA – Neural Cancer – Hereditary 22

Available

Genes:

ALK, CDKN1B, MEN1, NF1, NF2, PHOX2B, POT1, PRKAR1A, PTCH1, RB1, SDHA, SDHAF2, SDHB, SDHD*, SMARCA4, SMARCB1, SMARCE1, SUFU, TSC1, TSC2, GPC3, WRN

Useful for:

Our DNA – Neural Cancer – Hereditary 22 Panel is a targeted resequencing assay for the biomarker analysis of 22 genes with known relevance to hereditary neural tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 22 genes known to be associated with hereditary neural cancer syndromes.

DNA – Neural Cancer – Hereditary 12

Available

Genes:

APC, ATM, CDKN2A, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, TP53, VHL

Useful for:

Our DNA – Neural Cancer – Hereditary 12 Panel is a targeted resequencing assay for the biomarker analysis of 12 genes with known relevance to hereditary neural tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 12 genes known to be associated with hereditary neural cancer syndromes.

DNA – Pan Cancer – Hereditary 100

Available

Genes:

APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMAD4, TP53, VHL, BLM, PRSS1, SLX4, BAP1, ALK, CDKN1B, FH , FLCN, GREM1, HOXB13, MAX, MEN1, MET , MITF, NF1, NF2, PHOX2B, POLE, POT1 , PRKAR1A, PTCH1, RB1, RET , SDHA, SDHAF2, SDHB, SDHC, SDHD , SMARCA4, SMARCB1, SMARCE1, STK11 , SUFU, TMEM127, TSC1 , TSC2 , KIT, TERT promoter, KDR, PDGFRA, CDC73, CYLD, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, GATA2, GPC3, RECQL4, SBDS, WRN, WT1, XPA, XPC, RUNX1, CEP57, BUB1B, HRAS , IGF1, PRF1, FANCD2, FANCE, FANCF, FANCG, MPL, FANCC , HNF1A, TGFBR2, FANCA, FANCB

Useful for:

Our DNA – Pan Cancer – Hereditary 100 Panel is a targeted resequencing assay for the biomarker analysis of 100 genes with known relevance to hereditary tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 100 genes known to be associated with hereditary cancer syndromes.

DNA – Pan Cancer – Hereditary 69

Available

Genes:

BAP1, ALK, CDKN1B, FH , FLCN, GREM1, HOXB13, MAX, MEN1, MET , MITF, NF1, NF2, PHOX2B, POLE, POT1 , PRKAR1A, PTCH1, RB1, RET , SDHA, SDHAF2, SDHB, SDHC, SDHD , SMARCA4, SMARCB1, SMARCE1, SUFU, TMEM127, TSC1 , TSC2 , KIT, TERT promoter, KDR, PDGFRA, CDC73, CYLD, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, GATA2, GPC3, RECQL4, SBDS, WRN, WT1, XPA, XPC, RUNX1, CEP57, BUB1B, HRAS , IGF1, PRF1, FANCD2, FANCE, FANCF, FANCG, MPL, FANCC , HNF1A, TGFBR2, FANCA, FANCB

Useful for:

Our DNA – Pan Cancer – Hereditary 69 Panel is a targeted resequencing assay for the biomarker analysis of 69 genes with known relevance to hereditary tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 69 genes known to be associated with hereditary cancer syndromes.

DNA – Pan Cancer – Hereditary 31

Available

Genes:

APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMAD4, TP53, STK11, VHL, BLM, PRSS1, SLX4

Useful for:

Our DNA – Pan Cancer – Hereditary 31 Panel is a targeted resequencing assay for the biomarker analysis of 31 genes with known relevance to hereditary tumor formation and targeted therapeutic decisions.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses DNA isolated from whole blood to assess common somatic mutations and rearrangements (fusions) involving 31 genes known to be associated with hereditary cancer syndromes.

DNA – BRCA1/BRCA2 – Hereditary Focus

Available

Genes:

BRCA1, BRCA2

Useful for:

Our DNA – BRCA1/BRCA2 – Hereditary Focus is a targeted resequencing assay for the biomarker analysis of the breast-tumor-related BRCA1 and BRCA2 genes, providing assistance in targeted therapeutic decision making.

Method:

PCR amplification and Sanger sequencing.

DNA – BRCA1/BRCA2 – Hereditary

Available

Genes:

BRCA1, BRCA2

Useful for:

Our DNA – BRCA1/BRCA2 – Hereditary Panel is a targeted resequencing assay for the biomarker analysis of the breast-tumor-related BRCA1 and BRCA2 genes, providing assistance in targeted therapeutic decision making.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across the genes known to be associated with hereditary predisposition to different cancer types. This is a single assay that uses genomic DNA from whole blood to assess mutations and rearrangements (CNVs) involving the BRCA1 and BRCA2 genes known to be associated with breast and ovarian cancer predisposition.

RNA – Prostate Cancer – Solid 13

Under development

Genes:

PCA3, HOXC6, AR, ACTB, HPN, FOLH1, KLK2, AMACR, GAPDH, FOXA1, SPOP
Fusion: ERG, TMPRSS2

Useful for:

Our RNA – Prostate Cancer – Solid 13 Panel is a targeted resequencing assay for the biomarker analysis of 13 genes with known relevance to prostate tumors. Within these 13 genes, 25 targets are specifically examined.

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations involving 13 genes known to be associated with prostate cancer. The results of this test can be useful in assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Melanoma Cancer – Solid 10

Under development

Genes:

BRAF, ERBB2, GNA11, GNAQ , HRAS, KIT, MAP2K1, NRAS, PIK3CA, TP53

Useful for:

Our DNA – Melanoma Cancer – Solid 10 Panel is a targeted resequencing assay for the biomarker analysis of 10 genes with known relevance to melanomas. Within these 10 genes, 35 targets are specifically examined.

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations involving 10 genes known to be associated with melanomas. The results of this test can be useful in assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Lung Cancer – Solid 14

Available

Genes:

ALK1, BRAF, EGFR, GNA11, GNAQ, HRAS, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, TP53

Useful for:

Our DNA – Lung Cancer – Solid 14 Panel is a targeted resequencing assay for the biomarker analysis of 14 genes with known relevance to lung tumors. Within these 14 genes, 33 targets are specifically examined.

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations involving 14 genes known to be associated with lung cancer. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Breast Cancer – Solid 12

Available

Genes:

AKT1, CDH1, EGFR, ESR1, FGFR1, FGFR4, HER2, HRAS, KRAS, MET, PIK3CA, TP53

Useful for:

Our DNA – Breast Cancer – Solid 12 is a targeted resequencing assay for the analysis of hotspots in 12 gene with known relevance to breast cancer therapies. The following 34 hotspot mutations of the 14 breast cancer-related genes are monitored: AKT1 E17K, ANK3 E1083, CDH1 Q23*, EGFR E709, EGFR G719, EGFR S720, EGFR del K745-N750, EGFR L585, EGFR L861, FGFR1 K656, HER2 G309, HER2 S310, HER2 L755, HER2 D769, HER2 V777, HRAS G12, HRAS G13, HRAS Q61, KRAS G12, KRAS G13, KRAS Q61, MET T1003, PIK3CA E542, PIK3CA E545, PIK3CA H1047

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations involving 12 genes known to be associated with breast cancer. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Melanoma Cancer – Solid 76

Available

Genes:

ABL1, AKT1, AKT2, AKT3, ALK, APC, ARID1A, ARID1B, ARID2, ATM, ATRX, BCL2, BRAF, BRCA1, BRCA2, CDK4, CDK6, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, EPHB4, ERBB2, ERBB3, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, IDH1, IDH2, IGF1R, ITK, JAK1, JAK2, KDR, KIT, MDM2, MET, MLH1, MSH2, MSH6, MTOR, NF1, NOTCH1, NRAS, NTRK1, PALB2, PDGFRA, PDGFRB, PIK3CA, PTCH1, PTCH2, PTEN, PTPN11, RET, ROS1, SLX4, SMO, SRC, STK11, SYK, TERT, TOP1, TP53, Fusions: BRCA1, ERBB2, FGFR1, FGFR2, FGFR3, MET

Useful for:

Our DNA – Melanoma Cancer – Solid 76 Panel is a targeted resequencing assay for the biomarker analysis of 76 genes with known relevance to melanomas. It is able to identify melanomas that harbor mutations responding to targeted therapies by detecting multiple gene targets within the 76 genes simultaneously.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 76 genes known to be associated with melanomas.

DNA – Melanoma Cancer – Solid 41

Available

Genes:

AKT1, ALK, APC, BRAF, CDK4, CDK6, CDKN2A, CTNNB1, DDR2, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HRAS, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MTOR, NOTCH1, NRAS, NTRK1, PDGFRA, PIK3CA, PTCH1, PTEN, PTPN11, RB1, RET, SRC, STK11, TP53 Fusions: ALK, NTRK1, RET

Useful for:

Our DNA – Melanoma Cancer – Solid 41 Panel is a targeted resequencing assay for the biomarker analysis of 41 genes with known relevance to melanomas. It is able to identify melanomas that harbor mutations responding to targeted therapies by detecting multiple gene targets within the 41 genes simultaneously.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 41 genes known to be associated with melanomas.

DNA – Colorectal Cancer – Solid 93

Available

Genes:

ABL1, AKT1, AKT2, AKT3, ALK, APC, ARID1A, ARID1B, ARID2, ATM, ATRX, AURKA, AURKB, BARD1, BCL2, BLM, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDK6, CDKN2A, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, EPCAM, ERBB2, ERBB3, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MDM2, MET, MLH1, MPL, MRE11, MSH2, MSH6, MTOR, MUTYH, NF1, NOTCH1, NRAS, NTRK1, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3R1, PTCH1, PTEN, RB1, RET, ROS1, SLX4, SMAD4, SMO, SRC, STK11, TERT, TOP1, TP53, Fusions: BRCA1, ERBB2, FGFR1, FGFR2, FGFR3, MET, PDGFRA, PPARG, TMPRSS2

Useful for:

Our DNA – Colorectal Cancer – Solid 93 Panel is a targeted resequencing assay for the biomarker analysis of 93 genes with known relevance to colorectal tumors. It is able to identify colorectal tumors that harbor mutations responding to targeted therapies by detecting multiple gene targets within the 93 genes simultaneously.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 93 genes known to be associated with colorectal cancer.

DNA – Colorectal Cancer – Solid 43

Available

Genes:

ABL1, AKT1, ALK, APC, ATM, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDK6, CDKN2A, CTNNB1, EGFR, ERBB2, ERBB4, HRAS, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MTOR, MYC, MYCN, NOTCH1, NRAS, PDGFRA, PIK3CA, PTCH1, PTEN, RB1, RET, ROS1, SMAD4, SMO, SRC, STK11, TP53 Fusions: ALK, RET, ROS1

Useful for:

Our DNA – Colorectal Cancer – Solid 43 Panel is a targeted resequencing assay for the biomarker analysis of 43 genes with known relevance to colorectal tumors. It is able to identify colorectal tumors that harbor mutations responding to targeted therapies by detecting multiple gene targets within the 43 genes simultaneously.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 43 genes known to be associated with colorectal cancer.

DNA – Lung Cancer – Solid 78

Available

Genes:

AKT1, AKT2, AKT3, ALK, APC, ARID1A, ARID1B, ARID2, ATM, ATRX, BARD1, BCL2, BLM, BRAF, BRCA1, BRCA2, BRIP1, CDK4, CDK6, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, EPCAM, EPHB4, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MDM2, MET, MLH1, MTOR, NF1, NRAS, NTRK1, PDGFRA, PDGFRB, PIK3CA, PIK3R1, PRSS1, PTEN, RB1, RET, ROS1, SMAD4, SMO, SRC, STK11,TERT, TOP1, TP53, Fusions: BRCA1, ERBB2, FGFR1, FGFR2, FGFR3, MET, PDGFRA, TMPRSS2

Useful for:

Our DNA – Lung Cancer – Solid 78 Panel is a targeted resequencing assay for the biomarker analysis of 78 genes with known relevance to lung tumors. It is able to identify lung tumors that harbor mutations responding to targeted therapies by detecting multiple gene targets within the 78 genes simultaneously.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 78 genes known to be associated with lung cancer.

DNA – Lung Cancer – Solid 46

Available

Genes:

BRAF, CDK4, CDK6, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FGFR2, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MTOR, MYC, MYCN, NOTCH1, NRAS, NTRK1, PDGFRA, PIK3CA, PTCH1, PTEN, PTPN11, RB1, RET, ROS1, SMAD4, SMO, STK11, TP53 Fusions: ALK, NTRK1, RET, ROS1

Useful for:

Our DNA – Lung Cancer – Solid 46 Panel is a targeted resequencing assay for the biomarker analysis of 46 genes with known relevance to lung tumors. It is able to identify lung tumors that harbor mutations responding to targeted therapies by detecting multiple gene targets within the 46 genes simultaneously.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 46 genes known to be associated with lung cancer.

DNA – BRCA1/BRCA2 – Solid

Available

Genes:

BRCA1, BRCA2

Useful for:

Our DNA – BRCA1/BRCA2 – Solid Panel is a targeted resequencing assay for the biomarker analysis of the breast-tumor-related BRCA1 and BRCA2 genes, providing assistance in targeted therapeutic decision making.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving BRCA1 and BRCA2 genes known to be associated with cancer.

DNA – Breast Cancer – Solid 47

Available

Genes:

AKT1, AKT2, ALK, APC, ARID1A, ARID1B, ATM, ATRX, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK6, CDKN2A, CHEK2, EGFR, ERBB2, ERBB3, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HRAS, KIT, KRAS, MET, MLH1, MSH2, NBN, NF1, NOTCH1, NRAS, PALB2, PDGFRA, PIK3CA, PIK3R1, PMS2, PTEN, RB1, ROS1, SMAD4, STK11,TP53 Fusions: BRCA1, ERBB2, FGFR1, FGFR3, MET, PDGFRA,

Useful for:

Our DNA – Breast Cancer – Solid 47 Panel is a targeted resequencing assay for the biomarker analysis of 47 genes with known relevance to breast tumors. Our panel provides a better understanding of tumor behaviour and its likelihood to respond to a treatment thus enabling tailored medicine for the patient and frequently leading to a better outcome or reduced adverse effects.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 47 genes known to be associated with breast cancer.

DNA – Breast Cancer – Solid 28

Available

Genes:

AKT1, ALK, BRAF, BRCA1, BRCA2, CDH1, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR3, GNA11, GNAQ, HRAS, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, PTEN, RB1, ROS1, SMAD4,TP53 Fusions: ALK, NTRK1, RET, ROS1

Useful for:

Our DNA – Breast Cancer – Solid 28 Panel is a targeted resequencing assay for the biomarker analysis of 28 genes with known relevance to breast tumors. Our panel provides a better understanding of tumour behaviour and its likelihood to respond to a treatment thus enabling tailored medicine for the patient and frequently leading to a better outcome or reduced adverse effects.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 28 genes known to be associated with breast cancer.

DNA – Breast Cancer – Solid 28

Available

Genes:

AKT1, ALK, BRAF, BRCA1, BRCA2, CDH1, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR3, GNA11, GNAQ, HRAS, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, PTEN, RB1, ROS1, SMAD4,TP53 Fusions: ALK, NTRK1, RET, ROS1

Useful for:

Our DNA – Breast Cancer – Solid 28 Panel is a targeted resequencing assay for the biomarker analysis of 28 genes with known relevance to breast tumours. Our panel provides a better understanding of tumor behaviour and its likelihood to respond to a treatment thus enabling tailored medicine for the patient and frequently leading to a better outcome or reduced adverse effects.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 28 genes known to be associated with breast cancer.

DNA – Pan Cancer – Solid 109

Available

Genes:

ABL1, AKT1, AKT2, AKT3, ALK, APC, ARID1A, ARID1B, ARID2, ATM, ATRX, AURKA, AURKB, BARD1, BCL2, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDK6, CDKN2A, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, EPCAM, EPHB4, ERBB2, ERBB3, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, IGF1R, ITK, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MDM2, MET, MLH1, MPL, MRE11, MSH2, MSH6, MTOR, MUTYH, NBN, NF1, NOTCH1, NPM1, NRAS, NTRK1, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3R1, PMS2, PRSS1, PTCH1, PTCH2, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RB1, RET, ROS1, SLX4, SMAD4, SMARCB1, SMO, SRC, STK11, SYK, TERT, TOP1, TP53, VHL Fusions: BRCA1, ERBB2, EWSR1, FGFR1, FGFR2, FGFR3, MET, PDGFRA, PPARG, TMPRSS2

Useful for:

Our DNA – Pan Cancer – Solid 109 Panel is a targeted resequencing assay for the biomarker analysis of 109 genes with known relevance to solid tumors. Our panel provides a better understanding of tumor behavior and its likelihood to respond to a treatment thus enabling tailored medicine for the patient and frequently leading to a better outcome or reduced adverse effects.

Method:

Hybridization-based target capture and Next-Generation Sequencing. Next-Generation Sequencing emerged recently as an accurate and cost-effective method for the identification of alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses formalin-fixed paraffin-embedded tissues or cytology slides to assess common somatic mutations and rearrangements (fusions) involving 109 genes known to be associated with cancer.

DNA – Melanoma Cancer – Plasma Focus

Available

Genes:

BRAF, ERBB2, GNA11, GNAQ, HRAS, KIT, MAP2K1, NRAS, PIK3CA, TP53

Useful for:

Our DNA – Melanoma Cancer – Plasma Focus is a targeted resequencing assay for the analysis of hotspots in 10 genes with known relevance to melanoma therapies. The assay is circulating tumor DNA based and identifies variations from the plasma. ONE of the following 34 targets of the 10 melanoma related genes are monitored: BRAF c.1391-1406, BRAF V600, ERBB2 G309, ERBB2 S310, ERBB2 L755, ERBB2 D769, ERBB2 V777, GNA11 Q209, GNAQ Q209, HRAS G12, HRAS G13, HRAS Q61, KIT D52, KIT Y503-504insA, KIT M541, KIT K550-K558del, KIT V559, KIT V560, KIT L576, KIT D579, KIT K642, KIT V654, KIT C809, KIT D816, KIT D820, MAP2K1 P124, NRAS G12, NRAS G13, NRAS Q61, NRAS K117, NRAS A146, PIK3CA E542, PIK3CA E545 PIK3CA H1047, TP53 5.-8. exons. Method: PCR-amplification-based target enrichment and Next-Generation Sequencing

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses circulating tumor DNA purified from plasma to monitor common somatic mutations involving 10 genes known to be associated with melanomas. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Melanoma Cancer – Plasma 10

Available

Genes:

BRAF, ERBB2, GNA11, GNAQ , HRAS, KIT, MAP2K1, NRAS, PIK3CA, TP53

Useful for:

Our DNA – Melanoma Cancer – Plasma 10 is a targeted resequencing assay for the analysis of hotspots in 10 genes with known relevance to melanoma therapies. The assay is circulating tumor DNA based and identifies variations from the plasma. The following 34 targets of the 10 melanoma-related genes are monitored: BRAF c.1391-1406, BRAF V600, ERBB2 G309, ERBB2 S310, ERBB2 L755, ERBB2 D769, ERBB2 V777, GNA11 Q209, GNAQ Q209, HRAS G12, HRAS G13, HRAS Q61, KIT D52, KIT Y503-504insA, KIT M541, KIT K550-K558del, KIT V559, KIT V560, KIT L576, KIT D579, KIT K642, KIT V654, KIT C809, KIT D816, KIT D820, MAP2K1 P124, NRAS G12, NRAS G13, NRAS Q61, NRAS K117, NRAS A146, PIK3CA E542, PIK3CA E545 PIK3CA H1047, TP53 5.-8. exons. Method: PCR-amplification-based target enrichment and Next-Generation Sequencing

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses circulating tumor DNA purified from plasma to assess common somatic mutations involving 10 genes known to be associated with melanomas. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Lung Cancer – Plasma 14

Available

Genes:

ALK1, BRAF, EGFR, GNA11, GNAQ, HRAS, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, TP53

Useful for:

Our DNA – Lung Cancer – Solid 14 Panel is a targeted resequencing assay for the biomarker analysis of 14 genes with known relevance to lung tumors. Within these 14 genes 33 targets are specifically examined.

Method:

PCR-amplification-based target enrichment and Next-Generation Sequencing. Next-Generation sequencing emerged recently as an accurate and cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. This is a single assay that uses circulating tumor DNA purified from plasma to assess common somatic mutations involving 14 genes known to be associated with lung cancer. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – EGFR – Plasma Focus

Available

Genes:

EGFR

Useful for:

Our DNA – EGFR – Plasma Focus is a targeted resequencing assay for the analysis of hotspots in the EGFR gene exon 18-21 with known relevance to lung cancer therapies. The assay is circulating tumor DNA based and identifies variations from the plasma.

Method:

PCR-amplification-based target enrichment and Next Generation Sequencing. Next-generation sequencing has recently emerged as an accurate, cost-effective method to identify alterations across numerous genes known to be associated with response or resistance to specific targeted therapies. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumors. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.

DNA – Gut Microbiome Bacterial – Shotgun

Available

Target:

Bacterial composition of gut/stool.

Useful for:

Identifying and classifying all known bacterial species which have been sequenced and added to the reference genome database.

Method:

DNA is extracted from stool samples and processed for shotgun sequencing through fragmentation. The extracted DNA is then subjected to Next-generation sequencing methods, which have the ability and throughput to identify all bacterial species. This analysis provides valuable insights into overall gut health, allows measurement and quantification of different bacterial communities responsible for various conditions, and helps rebalance the gut microbiome after antibiotic stress or other non-beneficial impacts.

Services

Available

Genes:

Useful for:

Method: